IASIC Speaker Series Presents Cannabis and Psychosis

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed, organized, and guided by doctors.

 

Presented By: Brian Miller, MD, PhD, MPH
Date: Tuesday, November 23, 2021
Time: 1:00PM Eastern/10:00AM Pacific
Price: FREE

Substance use comorbidity in psychotic disorders has been described as “the rule rather than the exception”, and is often deleterious to the clinical course of illness. Cannabis (marijuana) is one of the most commonly used substances by patients with schizophrenia and related psychotic disorders. Modulation of the endocannabinoid system by the main psychoactive component in marijuana, Δ9-tetrahydrocannabinol, can induce acute psychosis and cognitive impairment. Over the past two decades, there has been extensive research on the association between cannabis and psychosis. The purpose of this presentation is to synthesize recent research in this area, including associations between cannabis and psychosis risk; the epidemiology and phenomenology of psychosis and comorbid cannabis use; and associations between cannabis use and clinical course, and outcomes in psychosis.

Like this article?

Share on facebook
Share on Facebook
Share on twitter
Share on Twitter
Share on linkedin
Share on Linkdin
Share on pinterest
Share on Pinterest

Leave a comment

Related Posts

What is THCP?

THCP, which is short for tetrahydrocannabiphorol and scientifically known as (-)-Trans-Δ9-tetrahydrocannabiphorol, is a natural cannabinoid and analog of THC present in varieties of cannabis. It’s thought to be 33 times more active at cannabinoid 1 (CB1) receptors than THC, causing an intense and intoxicating euphoric high. THCP’s legality is stuck between conflicting federal legislation. It’s not

Cannabis Legalization and Detection of Tetrahydrocannabinol (THC) in Injured Drivers

A recent study funded by the Canadian Institutes of Health Research found that after cannabis legalization, the prevalence of moderately injured drivers with a THC level of at least 2 ng per milliliter in participating British Columbia trauma centers more than doubled. The increase was largest among older drivers and male drivers. During the study

Cannabis Contaminants Limit Pharmacological Use of Cannabidiol

For nearly a century, Cannabis has been stigmatized and criminalized across the globe, but in recent years, there has been a growing interest in Cannabis due to the therapeutic potential of phytocannabinoids. With this emerging interest in Cannabis, concerns have arisen about the possible contaminations of hemp with pesticides, heavy metals, microbial pathogens, and carcinogenic compounds during the cultivation, manufacturing,

Scroll to Top